Cardiogenic shock due to myocardial infarction: Diagnosis, monitoring and treatment;Infarktbedingter kardiogener Schock - Diagnostik, Monitoring und Therapie

Deutsches Arzteblatt International

Volumn 109, Issue 19, 2012, Pages 343-351

  Werdan, Karl ^a   Rub, Martin ^b   Buerke, Michael ^c   Delle Karth, Georg ^d   Geppert, Alexander ^e   Schöndube, Friedrich A ^f  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^b Amper Kliniken AG   (Germany)

^c St Marien Krankenhaus Siegen gem GmbH   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e WILHELMINEN HOSPITAL   (Austria)

^f UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE; LEVOSIMENDAN; NORADRENALIN;

ACUTE HEART INFARCTION; ALGORITHM; ARTICLE; BLOOD FLOW; BLOOD PRESSURE; CARDIOGENIC SHOCK; CARDIOVASCULAR MORTALITY; CONSENSUS; COUNTERPULSATION; ERYTHROCYTE CONCENTRATE; EVIDENCE BASED PRACTICE; FIBRINOLYTIC THERAPY; FOLLOW UP; HEART INDEX; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE REVASCULARIZATION; HEART REHABILITATION; HUMAN; INFARCTION RELATED CARDIOGENIC SHOCK; INTENSIVE CARE; LUNG VENTILATION; MEDICAL SOCIETY; MULTIPLE ORGAN FAILURE; NUTRITION; OUTCOME ASSESSMENT; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; STRESS ULCER; SYSTEMIC THERAPY; THROMBOSIS;

EID: 84903362495     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2012.0343     Document Type: Article

References (26)

1. Nabel EG, Braunwald E: A tale of coronary artery disease and myocardial infarction. N Engl J Med 2012; 366: 54-63.
2. Hochman JS, Sleeper LA, Webb JG, et al.: Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 2006; 295: 2511-5.
3. Hochman JS, Sleeper LA, Webb JG, et al.: Early revasculari - zation in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock? N Engl J Med 1999; 341: 625-34.
4. Kohsaka S, Menon V, Lowe AM, et al.: Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med 2005; 165: 1643-50.
5. Van de Werf F, Bax J, Betriu A, et al.: Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008; 29: 2909-45.
6. Werdan K, Ruβ M, Buerke M, et al.: Deutsch-österreichische S3-Leitlinie Infarktbedingter kardiogener Schock. Diagnose, Monitoring und Therapie. Der Kardiologe 2011; 5: 166-224; Intensivmed 2011; 48: 291-344; Intensiv- und Notfallbehandlung 2011; 36: 49-130.
7. Hochman JS, Sleeper LA, White HD, et al.: One-year survival following early revascularization for cardiogenic shock. Jama 2001; 285: 190-2.
8. Arntz HR, Bossaert LL, Danchin N, Nikolaou NI: European Resuscitation Council Guidelines for Resuscitation 2010 Section 5. Initial management of acute coronary syndromes. Resuscitation 2010; 81: 1353-63.
9. Nolan JP, Soar J: Postresuscitation care: entering a new era. Curr Opin Crit Care 2010; 16: 216-22.
10. Cotter G, Moshkovitz Y, Kaluski E et al.: The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure. European Journal of Heart Failure 2003; 5: 443-51.
11. Fincke R, Hochman JS, Lowe AM et al.: Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: A report from the SHOCK trial registry. Journal of the American College of Cardiology 2004; 44: 340-8.
12. Mendoza DD, Cooper HA, Panza JA: Cardiac power output predicts mortality across a broad spectrum of patients with acute cardiac disease. Am Heart J 2007; 153: 366-70.
13. Russ MA, Prondzinsky R, Carter JM, et al.: Right ventricular function in myocardial infarction complicated by cardiogenic shock: Improvement with levosimendan. Crit Care Med 2009; 37: 3017-23.
14. De Backer D, Biston P, Devriendt J, et al.: Comparison of Dopamine and Norepinephrine in the treatment of shock. N Engl J Med 2010; 362: 779-89.
15. Sakr Y, Reinhart K, Vincent JL, et al.: Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit Care Med 2006; 34: 589-97.
16. Fuhrmann JT, Schmeisser A, Schulze MR, et al.: Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med 2008; 36: 2257-66.
17. Metra M, Nodari S, D'Aloia A, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: A randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. Journal of the American College of Cardiology 2002; 40: 1248-58.
18. Prondzinsky R, Lemm H, Swyter M, et al.: Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome. Crit Care Med 2010; 38: 152-60.
19. Unverzagt S, Machemer MT, Solms A, et al.: Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock. Cochrane Database Syst Rev 2011; CD007398.
20. Sjauw KD, Engstrom AE, Vis MM, et al.: A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-eleva - tion myocardial infarction: should we change the guidelines? Eur Heart J 2009; 30: 459-68.
21. Cyrus T, Mathews SJ, Lasala JM: Use of mechanical assist during high-risk PCI and STEMI with cardiogenic shock. Catheter Cardiovasc Interv 2010; 75(Suppl 1): 1-6.
22. Kouraki K, Schneider S, Uebis R, et al.: Characteristics and clinical outcome of 458 patients with acute myocardial infarction requiring mechanical ventilation. Results of the BEAT registry of the ALKK-study group. Clin Res Cardiol 2011; 100: 235-9.
23. Finfer S, Chittock DR, Su SY, et al.: Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283-97.
24. Cobb LA, Killip T, Lambrew CT, et al.: Glucose-insulin-potassium infusion and mortality in the CREATE-ECLA trial. Jama 2005; 293: 2597; Letters and authors' reply: 2005; 293: 2596-7.
25. The Triumph-Investigators: Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. Jama 2007; 297: 1657-66.
26. Thiele H, Schuler G, Neumann FJ, et al. on behalf of the IABPShock II Trial Investigators: Intraaortic balloon counterpulsation in myocardial infarction complicated by cardiogenic shock: Design and rational of the intraaortic balloon pump in cardiogenic shock II trial (IABP-SHOCK II). Am Heart J, 2012, in press.